A randomised phase 3 clinical trial is currently underway to assess the combination of IDH inhibitors with induction, consolidation and maintenance therapies in newly diagnosed IDH-mutant AML patients that are eligible for intensive chemotherapy (NCT03839771). This evidence concerns the gene IDH2 and acute myeloid leukemia.